ArticleSignal transduction and targeted therapy2026
SSTN
Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Despite therapeutic advances, multiple myeloma (MM) remains incurable, largely due to relapse and the emergence of drug resistance driven by clonal evolution and alterations in the bone marrow (BM) microenvironment that support tumor survival. This highlights the need for novel therapeutics targeting both tumor cells and the supportive BM niche, particularly for patients with relapsed/refractory MM. Syndecan-1 (Sdc1/CD138), a heparan sulfate proteoglycan, is abundantly expressed on both the surface of myeloma cells and within the MM microenvironment. It plays a critical role in MM pathogenesis by promoting cell survival, angiogenesis, and immune evasion. This study investigates a novel chimeric peptide, SSTN
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.